Reaktion #1122389

ord-17cfd2f691af4f06b27356a645f476f9

Reaktionsgleichung

c1cc(OC2CNC2)ccc1CN1CCC1
41A
c1cc(OC2CNC2)ccc1CN1CCC1
1-(4-(Azetidin-3-yloxy)benzyl)azetidine
CCOC(=O)c1nnc(-c2ccc(OC)cc2)o1
ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate
COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CCC5)cc4)C3)o2)cc1
41
Ausbeute 68.0%
COc1ccc(-c2nnc(C(=O)N3CC(Oc4ccc(CN5CCC5)cc4)C3)o2)cc1
(3-(4-(Azetidin-1-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone
Ausbeute 68.0%

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Vorschrift

Using a similar protocol as described in Example 36 employing 41A (0.10 g, 0.46 mmol) and ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate (0.13 g, 0.52 mmol) as starting materials afforded 130 mg (68%) of 41 as a solid. 1H NMR (500 MHz, CDCl3): δ 2.08 (m, 2H), 3.19 (t, 4H), 3.51 (s, 2H), 3.89 (s, 3H), 4.32 (d, 1H), 4.64 (dd, 1H), 4.74 (d, 1H), 5.06 (m, 1H), 5.11 (m, 1H), 6.72 (d, 2H), 7.02 (d, 2H), 7.21 (d, 2H), 8.10 (d, 2H), MS (APCI+) m/z 421 [M+H]+, LC purity: 95%.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08546375B2uspto-grants-2013_10